• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Helus Pharma Inc. - Common Stock (NQ:HELP)

10.81 +0.43 (+4.14%)
Delayed Quote Updated: 1:41 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 709,627
Open 10.30
Bid (Size) 10.80 (300)
Ask (Size) 10.83 (300)
Prev. Close 10.38
Today's Range 10.13 - 10.83
52wk Range 3.760 - 15.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints CNS Drug Development Veteran Suresh Durgam to Board of Directors
Today 9:15 EDT
Via Investor Brand Network
News headline image
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Today 7:30 EDT
From Helus Pharma Inc.
Via GlobeNewswire

Performance

52-Week Range 28.6% below 52-week high
10.81
3.7652W Low 15.1552W High
1 Week 15.1% below 1-week high
9.971W Low 12.731W High

Helus Pharma Inc. - Common Stock (HELP) traded between $3.76 and $15.15 over the past 52 weeks and last traded at $10.81, 28.6% below its 52-week high. Over the past week it ranged between $9.97 and $12.73.

Past 12 Months
+0.8%
-20.6%
+66.1%
+96.5%
+39.8%
+39.8%
1W +$0.09
1M -$2.80
3M +$4.30
6M +$5.31
YTD +$3.08
1Y +$3.08

HELP was +39.8% over the past year, +96.5% over six months, +39.8% year to date, +0.8% in the last week.

12 Months vs Market
HELP
+39.8%
DIA
+12.6%
SPY
+16.5%
QQQ
+21.4%
IWM
+10.4%

Over the past 12 months HELP returned +39.8% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.5%, QQQ (Nasdaq 100) +21.4% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.39× 3-mo avg
Today 709,627 3-mo avg 1.8M
1W
1.9M
1M
1.8M
3M
1.8M
6M
1.5M
YTD
1.3M
1Y
1.3M

HELP most recently traded 709,627 shares against a 3-month average daily volume of 1.8M.

More News

Read More
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Host Investor Presentation Highlighting Depression and Anxiety Treatment Programs on Oct. 21
October 08, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Host Investor Presentation on October 21, 2026
October 08, 2026
From Helus Pharma Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.
October 01, 2026
Via Investor Brand Network
TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
August 14, 2026
Via Investor Brand Network
News headline image
Helus Pharma Announces Completion of Legal Name Change
October 01, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗
September 24, 2026
Via MarketBeat
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
September 23, 2026
Via Investor Brand Network
News headline image
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
September 22, 2026
From Helus Pharma
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
September 22, 2026
Via Investor Brand Network
News headline image
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗
September 22, 2026
Via MarketBeat
News headline image
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
September 21, 2026
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026
September 21, 2026
Via Investor Brand Network
News headline image
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
September 21, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗
September 21, 2026
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗
September 20, 2026
Via MarketBeat
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference
September 10, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
September 10, 2026
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 09, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
September 09, 2026
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference
September 03, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
September 03, 2026
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
August 18, 2026
Via Investor Brand Network
News headline image
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
August 18, 2026
From Helus Pharma
Via GlobeNewswire

Frequently Asked Questions

Is Helus Pharma Inc. - Common Stock publicly traded?
Yes, Helus Pharma Inc. - Common Stock is publicly traded.
What exchange does Helus Pharma Inc. - Common Stock trade on?
Helus Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Helus Pharma Inc. - Common Stock?
The ticker symbol for Helus Pharma Inc. - Common Stock is HELP on the Nasdaq Stock Market
What is the current price of Helus Pharma Inc. - Common Stock?
The current price of Helus Pharma Inc. - Common Stock is 10.81
When was Helus Pharma Inc. - Common Stock last traded?
The last trade of Helus Pharma Inc. - Common Stock was at 10/15/26 01:41 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap